⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30842861 | 0.84 | HTT (0.39) | — | |
| SCHEMBL11200729 | 0.78 | KDM4E (0.32) | — | |
| SCHEMBL21274619 | 0.75 | MGMT (0.35) | — | |
| SCHEMBL6948806 | 0.75 | JAK2 (0.32) | — | |
| SCHEMBL1797757 | 0.74 | ALDH1A1 (0.50) | — | |
| SCHEMBL9936008 | 0.74 | KDM4E (0.32) | — | |
| SCHEMBL5184898 | 0.73 | ADORA3 (0.32) | — | |
| Hydrochloric Acid SCHEMBL21174542 | 0.73 | KDM4E (0.32) | — | |
| SCHEMBL7420623 | 0.70 | PARP1 (0.30) | — | |
| SCHEMBL28024950 | 0.69 | HRH3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | claimed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | claimed |
| US-9878050-B2 | Delivery of agents using interfering nanoparticles | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170182177-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-06-29 | — | — | US | disclosed |
| US-9526693-B2 | Delivery of agents using interfering nanoparticles | Sanford-Burnham Medical Research Inslilute (US) | 2016-12-27 | — | — | US | disclosed |
| US-20110263514-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011116152-A2 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD -BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
| US-7951784-B2 | modified small interfering RNAs (siRNAs) that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA; gene expression inhibition; for treating amyotrophic lateral sclerosis associated with the activity of a protein specified by a target mRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1986699-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1986609-A2 | RNA SILENCING AGENTS FOR USE IN THERAPY AND NANOTRANSPORTERS FOR EFFICIENT DELIVERY OF SAME | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080125386-A1 | RNA interference agents for therapeutic use | UNIVERSTIY OF MASSACHUSETTS (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2007092182-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007089607-A2 | RNA SILENCING AGENTS FOR USE IN THERAPY AND NANOTRANSPORTERS FOR EFFICIENT DELIVERY OF SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | disclosed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | disclosed |